Literature DB >> 1919577

Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease.

D Ben-Shachar1, P Riederer, M B Youdim.   

Abstract

The vulnerability of substantia nigral (SN) melaninized dopamine neurons to neurodegeneration in Parkinson's disease and the selective increases of iron and basal lipid peroxidation in SN indicate that iron-melanin interaction could be crucial to the pathogenesis of this disease. The present study describes, for the first time, the identification and characterization of a high-affinity (KD = 13 nM) and a lower affinity (KD = 200 nM) binding site for iron on dopamine melanin. The binding of iron to melanin is dependent on pH and the concentration of melanin. Iron chelators, U74500A, desferrioxamine, and to less extent 1,10-phenanthroline and chlorpromazine, but not the Parkinson-inducing neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, can inhibit the binding of iron to melanin and iron-induced lipid peroxidation. Although melanin alone diminishes basal lipid peroxidation in rat cortical homogenates, it can also potentiate that initiated by iron, a reaction inhibited by desferrioxamine. In the absence of an identifiable exogenous or endogenous neurotoxin in idiopathic Parkinson's disease, iron-melanin interaction in pars compacta of SN may be a strong candidate for the cytotoxic component of oxygen radical-induced neurodegeneration of melaninized dopamine neurons.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1919577     DOI: 10.1111/j.1471-4159.1991.tb06358.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  55 in total

1.  Effect of chronic variate stress on thiobarbituric-acid reactive species and on total radical-trapping potential in distinct regions of rat brain.

Authors:  L P Manoli; G D Gamaro; P P Silveira; C Dalmaz
Journal:  Neurochem Res       Date:  2000-07       Impact factor: 3.996

Review 2.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.

Authors:  Alessandra Gaeta; Robert C Hider
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 3.  Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity.

Authors:  F Tribl; K Marcus; G Bringmann; H E Meyer; M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2006-07-13       Impact factor: 3.575

Review 4.  Functional effects of neuromelanin and synthetic melanin in model systems.

Authors:  K L Double
Journal:  J Neural Transm (Vienna)       Date:  2006-05-05       Impact factor: 3.575

5.  Nanoparticle and iron chelators as a potential novel Alzheimer therapy.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  Methods Mol Biol       Date:  2010

6.  Lipid peroxides are generated by the fetal rat brain after episodes of global ischemia in utero.

Authors:  S Glozman; E Yavin
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

7.  Model neuromelanins as antioxidative agents during lipid peroxidation.

Authors:  T Wilczok; K Stepien; A Dzierzega-Lecznar; A Zajdel; A Wilczok
Journal:  Neurotox Res       Date:  1999-12       Impact factor: 3.911

Review 8.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  X-ray absorption fine-structure spectroscopy studies of Fe sites in natural human neuromelanin and synthetic analogues.

Authors:  A J Kropf; B A Bunker; M Eisner; S C Moss; L Zecca; A Stroppolo; P R Crippa
Journal:  Biophys J       Date:  1998-12       Impact factor: 4.033

10.  Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease.

Authors:  Tomás González-Hernández; Ignacio Cruz-Muros; Domingo Afonso-Oramas; Josmar Salas-Hernandez; Javier Castro-Hernandez
Journal:  Front Neuroanat       Date:  2010-10-20       Impact factor: 3.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.